Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (GB:0R1F)
LSE:0R1F
Holding GB:0R1F?
Track your performance easily
0R1F Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$39.35 - $61.07
Previous Close$56.56
Volume7.67K
Average Volume (3M)29.95K
Market Cap
$114.19B
Enterprise Value$155.90B
Total Cash (Recent Filing)$8.09B
Total Debt (Recent Filing)$49.75B
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Feb 06, 2025EPS Estimate
$1.47Next Dividend Ex-Date
Jan 03, 2025Dividend Yield4.26%
Share Statistics
EPS (TTM)-3.60
Shares Outstanding2,028,176,674
10 Day Avg. Volume92,182
30 Day Avg. Volume29,945
Standard Deviation0.07
R-Squared0.10
Alpha0.00420
Financial Highlights & Ratios
Price to Book (P/B)6.71
Price to Sales (P/S)2.41
Price to Cash Flow (P/CF)5.10
P/FCF Ratio5.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.29
Enterprise Value/Gross Profit4.54
Enterprise Value/Ebitda34.29
Forecast
1Y Price Target
$60.00Price Target Upside6.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Bristol-Myers Squibb News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceImproved visibility on profit and loss statements suggests that concerns over earnings per share falling below a certain threshold are diminishing.
Product Launch And Market PotentialCobenfy is projected to become a $10 billion-plus drug, with confidence in its launch for schizophrenia and potential in Alzheimer's psychosis and Bipolar 1 disorder.
Stock Performance And RatingThe upgrade from Market Perform to Outperform and the increase in price target from $55 to $73 suggests confidence in the stock's future performance.
Bears Say
Earnings GuidanceManagement only raised its '24 EPS midpoint guidance by $0.10, which implies a 4Q EPS range below current consensus.
Patent ExpirationBristol-Myers Squibb Company is facing significant challenges due to ongoing and imminent patent expirations for key products like Revlimid, Eliquis, and Opdivo.
Product LaunchesSotyktu, Zeposia, and Krazati launches remain underwhelming.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.07% Insiders
21.73% Mutual Funds
15.45% Other Institutional Investors
38.53% Public Companies and
Individual Investors
0R1F FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest share price was $39.35 and its highest was $61.07 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Currently, no data Available
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Feb 06, 2025 which is in 47 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Oct 31, 2024. The company reported $1.8 earnings per share for the quarter, beating the consensus estimate of $1.494 by $0.306.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.62 which represents an annual dividend yield of 4.26%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is $1.47.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,028,176,600 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $1.8 in its last earnings report, beating expectations of $1.494. Following the earnings report the stock price went up 5.191%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Among the largest hedge funds holding Bristol-Myers Squibb’s share is PRIMECAP Management Co. It holds Bristol-Myers Squibb’s shares valued at 1B.
---
Bristol-Myers Squibb Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$60.00 (6.09% Upside)
$60.00 (6.09% Upside)
Blogger Sentiment
Bullish
GB:0R1F Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $61.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.18%
12-Months-Change
Fundamentals
Return on Equity
-31.46%
Trailing 12-Months
Asset Growth
2.64%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
---
0R1F Company Deck
---
0R1F Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook, with strong performance from the growth portfolio, significant advancements in the pipeline, and successful approval and launch of new products like Cobinfi. However, challenges remain in achieving broader access for certain products and managing inventory impacts. The company's financial discipline and raised guidance further support a positive sentiment.Read More>---
0R1F Revenue Breakdown
27.12% Eliquis
20.02% Opdivo
13.55% Revlimid
8.00% Orencia
31.31% Other
---
0R1F Stock 12 Month Forecast
Average Price Target
$60.00
▲(6.09% Upside)
Technical Analysis
Bristol-Myers Squibb
―
Merck & Company
―
Pfizer
―
Johnson & Johnson
―
Eli Lilly & Co
―
Best Analysts Covering 0R1F
1 Year
1 Year Success Rate
13/20 ratings generated profit
1 Year Average Return
+5.06%
reiterated a sell rating last month
Copying Terence Flynn's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +5.06% per trade.
---